Guangji Pharmaceutical

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about
Guangji Pharmaceutical, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Guangji Pharmaceutical please access Flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Guangji Pharmaceutical, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Guangji Pharmaceutical please access Flcube.com

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers
CompanyDrug

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its three drug candidates – BL-M07D1, BL-M05D1, and izalontamab bretecan – have been granted Breakthrough Therapy Designation (BTD) by the Center…

Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Haisco's HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder
CompanyDeals

Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder

Hubei Guangji Pharmaceutical Expands Ex-Hospital Market Presence with New Partnerships
CompanyDeals

Hubei Guangji Pharmaceutical Expands Ex-Hospital Market Presence with New Partnerships

CompanyDeals

Hubei Guangji Pharmaceutical Partners with Jiangnan University for Green Manufacturing Innovation Lab